Showing results (31-40 of 107) with videos related to

Sort By:
Pageof 11
Diseases of the Colon and Rectum|June 9, 2009
Treatment for patients with rectal cancer and a clinical complete response to neoadjuvant therapy: a decision analysisHeather B Neuman, Elena B Elkin, Jose G Guillem, et al.
Annals of Surgery|January 2, 2007
A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservationJose G Guillem, David B Chessin, Jinru Shia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2011
Challenging the feasibility and clinical significance of current guidelines on lymph node examination in rectal cancer in the era of neoadjuvant therapyAnand Govindarajan, Mithat Gönen, Martin R Weiser, et al.
The American Journal of Surgical Pathology|December 23, 2004
Value of immunohistochemical detection of DNA mismatch repair proteins in predicting germline mutation in hereditary colorectal neoplasmsJinru Shia, David S Klimstra, Khedoudja Nafa, et al.
Diseases of the Colon and Rectum|May 11, 2002
Predictors of survival in recurrent rectal cancer after resection and intraoperative radiotherapyMargo Shoup, Jose G Guillem, Kaled M Alektiar, et al.
Familial Cancer|November 2, 2004
A636P testing in Ashkenazi JewsJose G Guillem, Harvey G Moore, Crystal Palmer, et al.
Annals of Surgical Oncology|November 5, 2004
Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcomeHarvey G Moore, Jinru Shia, David S Klimstra, et al.
Diseases of the Colon and Rectum|January 26, 2024
Factors Associated With Performing IPAA After Total Colectomy for Ulcerative ColitisKevin A Chen, Joyce Pak, Chris B Agala, et al.
Diseases of the Colon and Rectum|May 28, 2004
Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapyRobert P Akbari, Philip B Paty, Jose G Guillem, et al.
Annals of Surgical Oncology|February 6, 2004
Residual mesorectal lymph node involvement following neoadjuvant combined-modality therapy: rationale for radical resection?Francesco Stipa, Alma Zernecke, Harvey G Moore, et al.
Pageof 11